The study, published Oct. 5, analyzed OptumLabs claims data from 2007 to 2017 to compare individuals offered a high-deductible plan to those with a traditional option. Read more about the methodology here.
The study’s authors, affiliated with Baltimore-based Johns Hopkins University, OptumLabs, Ithaca, N.Y.-based Cornell University and Cambridge, Mass-based Harvard University, found that those with high-deductible plans were 6.6 percent less likely to access treatment for substance use disorder.
“Although small in magnitude, these estimates are clinically relevant because [substance use disorder] is vastly undertreated,” the study’s authors wrote.
Research cited in the study indicates high-deductible plans reduce healthcare spending, but higher deductibles can lead members to forego care.
The study’s authors wrote that movement toward high-deductible health plans could be “exacerbating” undertreatment of substance use disorder.
Read the full study here.
At the Becker's 5th Annual Fall Payer Issues Roundtable, taking place November 2–3 in Chicago, payer executives and healthcare leaders will come together to discuss value-based care, regulatory changes, cost management strategies and innovations shaping the future of payer-provider collaboration. Apply for complimentary registration now.
